For at opretholde den kliniske effekt bør MPA- eksponeringen overvåges, og Mycophenolate mofetil Teva - doserne justeres i forhold til dette, når rifampicin administreres samtidigt.
It is recommended to monitor MPA exposure levels and to adjust Mycophenolate mofetil Teva doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.